FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037647656> ?p ?o ?g. }

• W3037647656 endingPage "167" @default.
• W3037647656 startingPage "156" @default.
• W3037647656 abstract "In East Asia, S-1 plus cisplatin (SP) is one of the standard first-line chemotherapy regimens for metastatic or recurrent gastric cancer (MRGC). Oxaliplatin is generally less toxic and more convenient to administer than cisplatin. This was a multicenter, phase III study assessing whether S-1/oxaliplatin (SOX) was non-inferior/superior to SP in terms of progression-free survival (PFS). Patients with MRGC were randomized 1:1 to receive either SOX (S-1 80 mg/m2/day on days 1–14; oxaliplatin 130 mg/m2 on day 1; every 3 weeks) or SP (S-1 80 mg/m2/day on days 1–14; cisplatin 60 mg/m2 on day 1; every 3 weeks [SP3]). Between October 2012 and October 2014, 338 patients were randomized. The median age was 56 years, and 51% of patients had measurable lesions. SOX was significantly non-inferior but not superior to SP3 in terms of PFS [median 5.6 versus 5.7 months; hazard ratio (HR) 0.85; 95% confidence interval (CI) 0.67–1.07]. In patients with measurable disease, objective response rates were similar between SOX and SP3 (58% versus 60%). Overall, the survival in both groups did not differ (median 12.9 versus 11.4 months; HR 0.86; 95% CI 0.66–1.11). Treatment was well tolerated in both arms. Anemia, leucopenia, neutropenia, febrile neutropenia, and oral mucositis were more common with SP3. In contrast, thrombocytopenia, nausea, vomiting, and peripheral neuropathy were more common with SOX. SOX was non-inferior to SP3. The two regimens were well tolerated with different toxicity profiles. The SOX regimen can be recommended as a first-line treatment for MRGC. ClinicalTrials.gov: NCT01671449" @default.
• W3037647656 created "2020-07-02" @default.
• W3037647656 creator A5005925636 @default.
• W3037647656 creator A5006577120 @default.
• W3037647656 creator A5024382887 @default.
• W3037647656 creator A5026250495 @default.
• W3037647656 creator A5028863978 @default.
• W3037647656 creator A5029249306 @default.
• W3037647656 creator A5038188064 @default.
• W3037647656 creator A5048145361 @default.
• W3037647656 creator A5053847518 @default.
• W3037647656 creator A5062021313 @default.
• W3037647656 creator A5066449485 @default.
• W3037647656 creator A5076196426 @default.
• W3037647656 creator A5085952795 @default.
• W3037647656 creator A5086616952 @default.
• W3037647656 creator A5089277539 @default.
• W3037647656 date "2020-06-28" @default.
• W3037647656 modified "2023-10-18" @default.
• W3037647656 title "Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)" @default.
• W3037647656 cites W1757407923 @default.
• W3037647656 cites W1966165324 @default.
• W3037647656 cites W2022609714 @default.
• W3037647656 cites W2040872961 @default.
• W3037647656 cites W2053700920 @default.
• W3037647656 cites W2099756738 @default.
• W3037647656 cites W2100439220 @default.
• W3037647656 cites W2108661938 @default.
• W3037647656 cites W2125062521 @default.
• W3037647656 cites W2127773543 @default.
• W3037647656 cites W2128328462 @default.
• W3037647656 cites W2131972171 @default.
• W3037647656 cites W2146471523 @default.
• W3037647656 cites W2146741104 @default.
• W3037647656 cites W2153836018 @default.
• W3037647656 cites W2161322092 @default.
• W3037647656 cites W2164411042 @default.
• W3037647656 cites W2171075804 @default.
• W3037647656 cites W2763064222 @default.
• W3037647656 cites W2766695855 @default.
• W3037647656 cites W2896699951 @default.
• W3037647656 cites W2897154408 @default.
• W3037647656 cites W2944951978 @default.
• W3037647656 doi "https://doi.org/10.1007/s10120-020-01101-4" @default.
• W3037647656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32596783" @default.
• W3037647656 hasPublicationYear "2020" @default.
• W3037647656 type Work @default.
• W3037647656 sameAs 3037647656 @default.
• W3037647656 citedByCount "25" @default.
• W3037647656 countsByYear W30376476562020 @default.
• W3037647656 countsByYear W30376476562021 @default.
• W3037647656 countsByYear W30376476562022 @default.
• W3037647656 countsByYear W30376476562023 @default.
• W3037647656 crossrefType "journal-article" @default.
• W3037647656 hasAuthorship W3037647656A5005925636 @default.
• W3037647656 hasAuthorship W3037647656A5006577120 @default.
• W3037647656 hasAuthorship W3037647656A5024382887 @default.
• W3037647656 hasAuthorship W3037647656A5026250495 @default.
• W3037647656 hasAuthorship W3037647656A5028863978 @default.
• W3037647656 hasAuthorship W3037647656A5029249306 @default.
• W3037647656 hasAuthorship W3037647656A5038188064 @default.
• W3037647656 hasAuthorship W3037647656A5048145361 @default.
• W3037647656 hasAuthorship W3037647656A5053847518 @default.
• W3037647656 hasAuthorship W3037647656A5062021313 @default.
• W3037647656 hasAuthorship W3037647656A5066449485 @default.
• W3037647656 hasAuthorship W3037647656A5076196426 @default.
• W3037647656 hasAuthorship W3037647656A5085952795 @default.
• W3037647656 hasAuthorship W3037647656A5086616952 @default.
• W3037647656 hasAuthorship W3037647656A5089277539 @default.
• W3037647656 hasBestOaLocation W30376476561 @default.
• W3037647656 hasConcept C121608353 @default.
• W3037647656 hasConcept C126322002 @default.
• W3037647656 hasConcept C141071460 @default.
• W3037647656 hasConcept C168563851 @default.
• W3037647656 hasConcept C207103383 @default.
• W3037647656 hasConcept C2775965419 @default.
• W3037647656 hasConcept C2776694085 @default.
• W3037647656 hasConcept C2777063308 @default.
• W3037647656 hasConcept C2778496288 @default.
• W3037647656 hasConcept C2778850193 @default.
• W3037647656 hasConcept C2780580376 @default.
• W3037647656 hasConcept C2780852908 @default.
• W3037647656 hasConcept C2780962732 @default.
• W3037647656 hasConcept C2992435398 @default.
• W3037647656 hasConcept C31760486 @default.
• W3037647656 hasConcept C44249647 @default.
• W3037647656 hasConcept C526805850 @default.
• W3037647656 hasConcept C71924100 @default.
• W3037647656 hasConcept C90924648 @default.
• W3037647656 hasConceptScore W3037647656C121608353 @default.
• W3037647656 hasConceptScore W3037647656C126322002 @default.
• W3037647656 hasConceptScore W3037647656C141071460 @default.
• W3037647656 hasConceptScore W3037647656C168563851 @default.
• W3037647656 hasConceptScore W3037647656C207103383 @default.
• W3037647656 hasConceptScore W3037647656C2775965419 @default.
• W3037647656 hasConceptScore W3037647656C2776694085 @default.
• W3037647656 hasConceptScore W3037647656C2777063308 @default.
• W3037647656 hasConceptScore W3037647656C2778496288 @default.

• next